Drug intelligence / Profile preview

IGF Oncology second candidate

Development stage: Preclinical
Lead developer: IGF Oncology
Modality: Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

IGF Oncology's second candidate is a preclinical-stage targeted chemotherapy designed for the treatment of late-stage ovarian cancer. The drug utilizes a proprietary mechanism of action to target a specific receptor that is highly overexpressed on cancer cells. While the identity of the receptor and the exact mechanism of the chemotherapy payload remain undisclosed, the company has indicated that human clinical trials are planned. This candidate follows the company's lead program, IGF-MTX, but operates through a distinct, proprietary pathway.

Beyond the preview

Go deeper on IGF Oncology second candidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGF Oncology second candidate.

Explore the full profile